JP3826132B2 - Wrinkle improving agent - Google Patents

Wrinkle improving agent Download PDF

Info

Publication number
JP3826132B2
JP3826132B2 JP2003417604A JP2003417604A JP3826132B2 JP 3826132 B2 JP3826132 B2 JP 3826132B2 JP 2003417604 A JP2003417604 A JP 2003417604A JP 2003417604 A JP2003417604 A JP 2003417604A JP 3826132 B2 JP3826132 B2 JP 3826132B2
Authority
JP
Japan
Prior art keywords
skin
wrinkle
farnesyl
wrinkles
improving agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003417604A
Other languages
Japanese (ja)
Other versions
JP2005179189A (en
Inventor
順一 松井
昭憲 原武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2003417604A priority Critical patent/JP3826132B2/en
Publication of JP2005179189A publication Critical patent/JP2005179189A/en
Application granted granted Critical
Publication of JP3826132B2 publication Critical patent/JP3826132B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Description

本発明は、老化に伴い、特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つ効果を有するファルネシル酢酸エステルを含有するシワ改善剤に関する。   The present invention relates to a wrinkle-improving agent containing farnesyl acetate having an effect of improving wrinkles generated at an exposed site with aging, and having an effect of keeping the skin in a dermatological and cosmetically healthy state.

ヒトをはじめとするすべての生物の臓器は、誕生して成長した後、加齢と伴に徐々に衰え、やがて機能停止し、機能停止した部分がある一定以上になると死に至る。その機能が徐々に衰えて行く状態を老化と呼んでいる。皮膚は、まわりの環境から直接影響を受けており、生体内部の環境を維持する重要な機能を持っているため全てが機能停止に至ることはあまりないが、シワ、シミ、くすみ、タルミなど老化徴候が顕在化しやすい臓器であり、日光に暴露される露光部位では特に顕著である。   Organs of all living organisms including humans are born and grow, then gradually decline with age, eventually stop functioning, and die when a certain part of the function is stopped. A state in which the function gradually declines is called aging. The skin is directly affected by the surrounding environment, and since it has an important function to maintain the environment inside the living body, it is unlikely that everything will stop functioning, but aging such as wrinkles, spots, dullness, tarmi, etc. This is an organ in which signs are easily manifested, and is particularly prominent in exposed areas exposed to sunlight.

皮膚の老化が進行すると、酸化ストレスなどの刺激に対する防御が弱まり、皮膚内部環境を乱す原因となり、さらに老化を進める。特に、露光部位では紫外線照射などが原因となる強い酸化ストレスに常に曝されていることから、老化の進行が顕著である。このような皮膚の変化を光老化と呼んでおり、そのような皮膚では、表皮が肥厚し、真皮では大多数を占める構成成分であるコラーゲンが減少することにより皮膚表面でシワが深く大きくなるなど美容上も好ましくない状態となる。   As skin aging progresses, defense against stimuli such as oxidative stress is weakened, causing the internal environment of the skin to be disturbed and further aging. In particular, since the exposed part is constantly exposed to strong oxidative stress caused by ultraviolet irradiation or the like, the progress of aging is remarkable. Such skin changes are called photoaging. In such skin, the epidermis is thickened, and the collagen, which is the major component in the dermis, decreases, causing wrinkles deeper and larger on the skin surface. This is also unfavorable for cosmetic purposes.

光老化が進行した結果生じるシワに対して改善効果を有する物質として、米国ではレチノイン酸が処方箋薬として用いられているが、副作用が強く安全性にも問題があるため、我が国では承認に至っていない。また、体内に吸収された後レチノイン酸に転換され効果を発揮すると言われているレチノール(ビタミンA)や抗酸化およびコラーゲン合成促進効果を持つアスコルビン酸(ビタミンC)、抗酸化効果の強いトコフェロール(ビタミンE)などシワ改善物質として提案されているが(例えば、特許文献1、特許文献2参照)、これらは十分に満足する効果が得られない欠点があった。したがって、これまでにシワを改善する物質として、十分に満足する効果を有し、安全性も有するものはなかった。
特開平7−165567号公報 特開昭62−164609号公報
In the United States, retinoic acid is used as a prescription drug as a substance that has an improvement effect on wrinkles caused by the progress of photoaging, but it has not been approved in Japan because of its side effects and safety issues. . In addition, retinol (vitamin A), which is said to be converted into retinoic acid after being absorbed into the body and exert its effect, ascorbic acid (vitamin C) having an antioxidant and collagen synthesis promoting effect, and tocopherol having a strong antioxidant effect ( Vitamin E) and the like have been proposed as wrinkle-improving substances (see, for example, Patent Document 1 and Patent Document 2), but these have a drawback that a sufficiently satisfactory effect cannot be obtained. Therefore, there has been no substance that has a sufficiently satisfactory effect and safety as a substance for improving wrinkles so far.
JP 7-165567 A JP 62-164609 A

本発明の目的は、老化により、特に露光部位で顕著に顕在化するシワの改善効果に優れ、美容的にも健やかな皮膚に保つ効果に優れたファルネシル酢酸エステルを配合することを特徴とするシワ改善剤を提供することにある。   An object of the present invention is to provide a wrinkle characterized by blending farnesyl acetate, which has an excellent effect of improving wrinkles that are noticeably manifested by aging, and has an effect of maintaining cosmetically healthy skin. It is to provide an improving agent.

本発明者らは、上記事情に鑑み、鋭意研究を行った結果、次のシワ改善剤が老化により、特に露光部位で顕著に出現するシワを改善し、美容的にも皮膚を健やかに保つ効果および安全性に優れることを確認して本発明を完成するに至った。すなわち、本発明は、下記一般式(1)

Figure 0003826132
(但し、式中Rは炭素原子数1〜9の直鎖又は分岐鎖状の、飽和又は不飽和炭化水素基を示す)で表されるファルネシル酢酸エステルの少なくとも一種以上を配合することを特徴とするシワ改善剤にある。 As a result of intensive studies in view of the above circumstances, the present inventors have improved the wrinkle that appears prominently at the exposed site due to aging, and the effect of keeping the skin healthy cosmetically. And it was confirmed that it was excellent in safety, and the present invention was completed. That is, the present invention provides the following general formula (1)
Figure 0003826132
(Wherein R represents a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 9 carbon atoms) and at least one kind of farnesyl acetate represented by: It is in the wrinkle improving agent.

本発明は、加齢に伴い特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つシワ改善剤を提供することができる。   INDUSTRIAL APPLICABILITY The present invention can provide a wrinkle improving agent that is excellent in improving wrinkles that occur particularly in exposed areas with aging and that keeps the skin in a dermatological and cosmetically healthy state.

以下、本発明の実施の形態を詳述する。ファルネシル酢酸エステルは、ファルネシル酢酸(5,9,13-trimethyl-4,8,12-tetradecatrienoic acid)と炭素原子数1〜9の直鎖又は分岐鎖状の飽和又は不飽和アルコールとのエステルである。炭素原子数1〜9の直鎖又は分岐鎖状の飽和又は不飽和アルコールを例示すると、メタノール、エタノール、プロパノール、2−プロパノール、ブタノール、2−ブタノール、ペンタノール、2−ペンタノール、3−ペンタノール、2−メチルブタノール、ジメチルプロパノール、ヘキサノール、ヘプタノール、オクタノール、2−エチルヘキサノール、4−エチルヘキサノール、ノナノール、アリルアルコール、クロチルアルコール、2−ブテノール、2−ペンテノール、3−ヘキセノール、2−ヘプテノール、フェノール、ベンジルアルコール等が挙げられる。   Hereinafter, embodiments of the present invention will be described in detail. Farnesyl acetate is an ester of farnesyl acetic acid (5,9,13-trimethyl-4,8,12-tetradecatrienoic acid) and a linear or branched saturated or unsaturated alcohol having 1 to 9 carbon atoms. . Examples of linear or branched saturated or unsaturated alcohols having 1 to 9 carbon atoms include methanol, ethanol, propanol, 2-propanol, butanol, 2-butanol, pentanol, 2-pentanol, and 3-pen. Tanol, 2-methylbutanol, dimethylpropanol, hexanol, heptanol, octanol, 2-ethylhexanol, 4-ethylhexanol, nonanol, allyl alcohol, crotyl alcohol, 2-butenol, 2-pentenol, 3-hexenol, 2- Examples include heptenol, phenol and benzyl alcohol.

上記一般式(1)中、Rで示される炭化水素基の炭素原子数は1〜9であり、更に好ましくは炭化水素基の炭素原子数が1〜5である。炭化水素基の炭素原子数が9を超えると溶解性が悪く、また使用感触上好ましくない。これらのファルネシル酢酸エステルは、通常市販されているものをそのまま、或いは蒸留等常法によって精製した後に使用することも可能でであり、公知のエステル化の方法でファルネシル酢酸と各種アルコールから、或いは市販品であるファルネシル酢酸ゲラニルエステルからのエステル交換反応により容易に合成することができる。   In the general formula (1), the hydrocarbon group represented by R has 1 to 9 carbon atoms, and more preferably the hydrocarbon group has 1 to 5 carbon atoms. When the number of carbon atoms of the hydrocarbon group exceeds 9, the solubility is poor and it is not preferable from the viewpoint of use. These farnesyl acetates can be used as they are commercially available as they are or after being purified by a conventional method such as distillation, and can be used from farnesyl acetate and various alcohols by a known esterification method or commercially available. It can be easily synthesized by a transesterification reaction from farnesyl acetic acid geranyl ester.

これらのファルネシル酢酸エステルは、それぞれ単独で配合しても、または2種以上を組み合わせて配合してもよい。また、これらのファルネシル酢酸エステルの配合量は、シワ改善剤の総量を基準としてそれぞれ0.001〜10.0質量%(以下、単に%と記する)が好ましい。ファルネシル酢酸エステルの配合量が0.001%未満では本発明の目的とする効果が十分に得られない場合があり、配合量が10.0%を越えても、その増加分に見合った効果の向上は望めない場合があり、また使用時の感触が悪くなり製剤化上支障をきたす傾向があるため好ましくない。   These farnesyl acetates may be blended singly or in combination of two or more. Further, the blending amount of these farnesyl acetates is preferably 0.001 to 10.0% by mass (hereinafter simply referred to as%) based on the total amount of the wrinkle improving agent. If the blended amount of farnesyl acetate is less than 0.001%, the intended effect of the present invention may not be sufficiently obtained. Even if the blended amount exceeds 10.0%, the effect commensurate with the increased amount. In some cases, improvement cannot be expected, and the feeling during use tends to be poor and the formulation tends to be hindered.

本発明のシワ改善剤は、皮膚化粧料や外用剤として医薬品や入浴剤等に適用でき、剤型としては、例えばローション類、乳液類、クリーム類、パック類等とすることができる。尚、本発明のシワ改善剤には上記の他に色素、香料、防腐剤、界面活性剤、顔料、抗酸化剤等を本発明の目的を達成する範囲内で適宜配合することができる。   The wrinkle improving agent of the present invention can be applied as a skin cosmetic or an external preparation to pharmaceuticals, bathing agents, etc., and the dosage form can be, for example, lotions, emulsions, creams, packs and the like. In addition to the above, a coloring matter, a fragrance, a preservative, a surfactant, a pigment, an antioxidant and the like can be appropriately blended with the wrinkle improving agent of the present invention as long as the object of the present invention is achieved.

以下、実施例及び比較例に基づいて本発明を詳説する。   Hereinafter, the present invention will be described in detail based on examples and comparative examples.

製造例1(ファルネシル酢酸メチルエステル)
メタノール(150mL)に金属ナトリウム(252mg)を加え、室温下30分間攪拌し、ナトリウムエトキシドを調製した。ここへファルネシル酢酸ゲラニルエステル(3.01g)のメタノール溶液(50mL)を加え、加熱還流下15時間攪拌した。室温まで冷却した後、酢酸(0.70mL)を加えて中和した。減圧下濃縮して得られた残渣を酢酸エチルで希釈し、これをろ過することにより析出した酢酸ナトリウムを除いた。ろ液を減圧濃縮し、シリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=50:1)、減圧蒸留により精製し、1.15gのファルネシル酢酸メチルエステルを無色油状で得た。
Production Example 1 (farnesyl acetate methyl ester)
Sodium metal (252 mg) was added to methanol (150 mL), and the mixture was stirred at room temperature for 30 minutes to prepare sodium ethoxide. A methanol solution (50 mL) of farnesyl acetic acid geranyl ester (3.01 g) was added thereto, and the mixture was stirred for 15 hours while heating under reflux. After cooling to room temperature, the mixture was neutralized by adding acetic acid (0.70 mL). The residue obtained by concentration under reduced pressure was diluted with ethyl acetate, and this was filtered to remove precipitated sodium acetate. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (hexane: ethyl acetate = 50: 1) and distillation under reduced pressure to obtain 1.15 g of farnesyl acetate methyl ester as a colorless oil.

製造例2(ファルネシル酢酸ブチルエステル)
ブタノール(150mL)に金属ナトリウム(246mg)を加え、室温下60分間攪拌し、ナトリウムブトキシドを調製した。ここへファルネシル酢酸ゲラニルエステル(3.01g)のブタノール溶液(50mL)を加え、110℃で15時間攪拌した。室温まで冷却した後、酢酸(0.70mL)を加えて中和した。減圧下濃縮して得られた残渣をジエチルエーテルで希釈し、これをろ過することにより析出した酢酸ナトリウムを除いた。ろ液を減圧濃縮し、シリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=50:1)、減圧蒸留により精製し、1.00gのファルネシル酢酸ブチルエステルを無色油状で得た。
Production Example 2 (farnesyl acetic acid butyl ester)
Sodium metal (246 mg) was added to butanol (150 mL), and the mixture was stirred at room temperature for 60 minutes to prepare sodium butoxide. A butanol solution (50 mL) of farnesyl acetic acid geranyl ester (3.01 g) was added thereto and stirred at 110 ° C. for 15 hours. After cooling to room temperature, the mixture was neutralized by adding acetic acid (0.70 mL). The residue obtained by concentration under reduced pressure was diluted with diethyl ether, and this was filtered to remove precipitated sodium acetate. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (hexane: ethyl acetate = 50: 1) and distillation under reduced pressure to obtain 1.00 g of farnesyl acetate butyl ester as a colorless oil.

実施例1(ファルネシル酢酸メチルエステル配合シワ改善剤)
製造例1のファルネシル酢酸メチルエステルを配合したシワ改善剤を、光老化させた皮膚に適用し、そのシワ改善効果を次の試験方法により調べた。
Example 1 (Farnesyl acetate methyl ester-containing wrinkle improving agent)
The wrinkle improving agent blended with farnesyl acetic acid methyl ester of Production Example 1 was applied to photoaged skin, and the wrinkle improving effect was examined by the following test method.

(試験方法)
1. 実験動物
試験開始時10週齢のヘアレスマウス1群10匹を用いた。
(Test method)
1. Experimental animals One group of 10 hairless mice aged 10 weeks at the start of the test was used.

2. シワ改善効果の測定
2−1.光老化条件
光老化は、UVAとUVBを1日1回、週5回、8週間照射することで誘発させた。照射量は、UVAが20J/cm、25J/cm、30J/cm、UVBが20mJ/cm、30mJ/cm、40mJ/cmと、1週ごとに照射量を増量し、3週目以降は最大量を照射した。
2. 2. Measurement of wrinkle improvement effect 2-1. Photoaging conditions Photoaging was induced by irradiating UVA and UVB once a day, 5 times a week for 8 weeks. Irradiation dose, UVA is increased with 20J / cm 2, 25J / cm 2, 30J / cm 2, UVB is 20mJ / cm 2, 30mJ / cm 2, 40mJ / cm 2, an irradiation amount for each 1 week, 3 After week, the maximum dose was irradiated.

2−2.シワ改善効果の評価方法
シワ改善効果はシワスコアと表皮厚により評価した。シワスコアは、Bissettらの方法(Photochem.Photobiol.46:367−378、1987)に従って採点した。すなわち、シワの大きさおよび深さを肉眼で総合的に評価し、「大きく深いシワが確認できる」を3、「シワが確認できる」を2、「シワが確認できない」を1、「正常なキメが観察される」を0の4段階で採点した。表皮厚の測定は、全層皮膚を採取して定法に従って皮膚切片標本を作製したのちヘマトキシリン・エオシン染色を施し、表皮の厚さを画像解析ソフト(マイクロアナライザー、日本ポラデジタル社製)で測定した。
2-2. Evaluation method of wrinkle improvement effect The wrinkle improvement effect was evaluated by the wrinkle score and skin thickness. The wrinkle score was scored according to the method of Bissett et al. (Photochem. Photobiol. 46: 367-378, 1987). That is, the size and depth of the wrinkle are comprehensively evaluated with the naked eye, 3 indicating that “a large and deep wrinkle can be confirmed”, 2 indicating “a wrinkle can be confirmed”, 1 indicating “a wrinkle cannot be confirmed”, and “normal” “The texture is observed” was scored on a scale of 0. The skin thickness was measured by collecting the skin of all layers and preparing a skin slice sample according to a standard method, then staining with hematoxylin and eosin, and measuring the thickness of the epidermis with image analysis software (Microanalyzer, manufactured by Pola Digital Japan). .

2−3.試料と操作
50%エタノール水溶液(基剤)に、製造例1で得られたファルネシル酢酸エステル1.0%を配合した試料を調製した(実施例1)。また基剤のみの試料を比較例1とした。
まず、これら試料0.1mLをヘアレスマウスの背部皮膚(直径約2.5cm)に1日1回、1週間に5回の頻度で、UV照射開始後5週目から照射終了後4週目まで塗布した。そして、塗布終了後にシワスコアを採点し、屠殺後、皮膚を採取し表皮厚を測定した。シワスコアと表皮厚ともに、基剤(比較例1)塗布群を対照として比較した。
2-3. Sample and Operation A sample was prepared by blending the 50% ethanol aqueous solution (base) with 1.0% farnesyl acetate obtained in Production Example 1 (Example 1). A sample containing only the base was used as Comparative Example 1.
First, 0.1 mL of these samples were applied to the back skin of a hairless mouse (diameter: about 2.5 cm) once a day at a frequency of 5 times a week from the fifth week after the start of UV irradiation to the fourth week after the end of irradiation. Applied. And after completion | finish of application | coating, the wrinkle score was scored, after slaughtering, the skin was extract | collected and epidermis thickness was measured. Both the wrinkle score and the skin thickness were compared using the base (Comparative Example 1) application group as a control.

(シワスコア評価結果)
−−−−−−−−−−−−−−−−−−−−−−−−−−
群 シワスコア値(値は平均値±SE)
−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例1塗布群 2.15 ± 0.09
比較例1塗布群 2.55 ± 0.11
−−−−−−−−−−−−−−−−−−−−−−−−−−
(Wrinkle score evaluation result)
-------------------------
Group Wrinkle score (value is mean ± SE)
-------------------------
Example 1 application group 2.15 ± 0.09
Comparative Example 1 application group 2.55 ± 0.11
-------------------------

実施例1のシワ改善剤塗布群では、比較例1塗布群と比較して有意に低いシワスコア値を示し、光老化により誘発したシワに対し、ファルネシル酢酸エステルが有効であることが示された。   The wrinkle improving agent application group of Example 1 showed a significantly lower wrinkle score value compared to the Comparative Example 1 application group, indicating that farnesyl acetate was effective against wrinkles induced by photoaging.

(表皮厚測定結果)
−−−−−−−−−−−−−−−−−−−−−−−−−−
群 表皮厚(μm、値は平均値±SE)
−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例1塗布群 36.88 ± 3.14
比較例1塗布群 41.16 ± 2.60
−−−−−−−−−−−−−−−−−−−−−−−−−−
(Skin thickness measurement result)
-------------------------
Group skin thickness (μm, values are mean ± SE)
-------------------------
Example 1 application group 36.88 ± 3.14
Comparative Example 1 Application Group 41.16 ± 2.60
-------------------------

実施例1のシワ改善剤塗布群では、比較例1塗布群と比較して有意に薄い表皮厚を示し、光老化により肥厚する表皮に対し、ファルネシル酢酸エステルが肥厚を軽減する効果を有することが示された。尚、レチノイン酸を本試験系に適用した場合、シワスコアおよびコラーゲン含有量には有効であるが、表皮厚に関しては肥厚を増進する方向に働き、この作用が安全性を問題視する一要因となっていた。それに比べ、ファルネシル酢酸メチルエステルにはそのような作用もなく、通常の安全性試験においても何等問題は無かった。   In the wrinkle improving agent application group of Example 1, the skin thickness is significantly thinner than that in the Comparative Example 1 application group, and farnesyl acetate has an effect of reducing the thickness on the skin thickened by photoaging. Indicated. In addition, when retinoic acid is applied to this test system, it is effective for the wrinkle score and collagen content, but the skin thickness works in the direction of increasing thickening, and this action is one factor that raises safety concerns. It was. In comparison, farnesyl acetic acid methyl ester had no such effect, and there was no problem in normal safety tests.

実施例2(ファルネシル酢酸ブチルエステル配合シワ改善剤)
製造例2のファルネシル酢酸ブチルエステルを配合したシワ改善剤に関し、上記実施例1と同様の試験によりシワ改善効果を確認したところ、対照である比較例1塗布群と比較して、シワスコア値において有意に低い値を、表皮厚において有意に薄い表皮厚を示した。
Example 2 (farnesyl butyl ester-containing wrinkle improving agent)
About the wrinkle improving agent which mix | blended farnesyl acetic acid butyl ester of manufacture example 2, when the wrinkle improvement effect was confirmed by the test similar to the said Example 1, compared with the comparative example 1 application group which is a control | contrast, it is significant in a wrinkle score value. The skin thickness was significantly lower in the skin thickness.

以上の結果から、実施例1、2のファルネシル酢酸エステルを配合したシワ改善剤が、比較例1と比較して明らかに、光老化によるシワを改善する効果を有することが示された。   From the above results, it was shown that the wrinkle improving agent containing the farnesyl acetate of Examples 1 and 2 clearly has an effect of improving wrinkles due to photoaging as compared with Comparative Example 1.

実施例3、比較例2(スキンローション)
下記組成のスキンローション(実施例3、比較例2)を下記の調製法に従って調製し、それを試料として以下に従ってシワ改善効果を評価した。
5名の目尻にシワのある健常人(女性、44〜55歳)を被検者として、実施例3及び比較例2のスキンローションそれぞれを、左右のどちらかに決めて、朝洗顔後、及び夕方入浴後の1日2回、2ヵ月間(60日)連続で目尻のシワの部分(各試料ごとに目尻を中心に約4cm、2×2cm)に約0.2mLずつ塗布してもらった。そして最終塗布後に左右の目尻部分の皮膚(シワ)の状態に関しアンケートに答えてもらった。
Example 3, Comparative Example 2 (skin lotion)
Skin lotions (Example 3, Comparative Example 2) having the following composition were prepared according to the following preparation method, and the wrinkle improvement effect was evaluated according to the following using the samples as samples.
Five healthy subjects with wrinkles in the corners of the eyes (female, 44-55 years old) were used as subjects, and the skin lotions of Example 3 and Comparative Example 2 were determined to be either left or right, after washing in the morning, and Twice a day after bathing in the evening for 2 months (60 days), apply about 0.2 mL of wrinkles on the corner of the eye (about 4 cm 2 , 2 x 2 cm centered on the corner of each eye for each sample). It was. Then, after the final application, they were asked to answer a questionnaire regarding the condition of the skin (wrinkles) on the left and right eye corners.

(組成)
原 料 成 分 配合量(%)
A成分
(1)オリーブ油 10.0
(2)ミリスチン酸イソプロピル 1.0
(3)モノラウリン酸
ポリオキシエチレン(20)ソルビタン 0.5
(4)プロピレングリコール 1.0
(5)グリセリン 2.0
B成分
(6)メチルパラベン 0.1
(7)エタノール 7.0
(8)精製水 残 量
C成分
(9)ファルネシル酢酸メチルエステル 2.0(実施例3)
または 0(比較例2)
(composition)
Ingredients Component Amount (%)
Component A (1) Olive oil 10.0
(2) Isopropyl myristate 1.0
(3) Monolauric acid polyoxyethylene (20) sorbitan 0.5
(4) Propylene glycol 1.0
(5) Glycerin 2.0
Component B (6) Methylparaben 0.1
(7) Ethanol 7.0
(8) Purified water remaining amount C component (9) Farnesyl acetic acid methyl ester 2.0 (Example 3)
Or 0 (Comparative Example 2)

(製法)
C成分のファルネシル酢酸メチルエステルをB成分に添加して均一に溶解した後、A成分を添加して混合撹拌分散し、次いで容器に充填した。使用時には内容物を均一に振盪分散して使用した。
(Manufacturing method)
The farnesyl acetic acid methyl ester of component C was added to component B and uniformly dissolved, then component A was added, mixed, stirred and dispersed, and then filled into a container. During use, the contents were uniformly shaken and dispersed.

アンケート結果をもとに、皮膚(シワ)の状態に関する各項目において、比較例2より実施例3のスキンローションのほうが有効であると回答した人数を以下に示す。   Based on the questionnaire results, the number of respondents who answered that the skin lotion of Example 3 is more effective than Comparative Example 2 for each item regarding the state of skin (wrinkles) is shown below.

−−−−−−−−−−−−−−−−−−−
項目 人数(名)
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった 5
皮膚が柔らかくなった 4
皮膚にハリがでた 5
皮膚につやがでた 3
皮膚があかるくなった 4
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 5
The skin became soft 4
The skin got firmer 5
Shining on the skin 3
My skin became moist 4
-------------------

本試験結果から実施例3のスキンローションは、比較例2と比較して明らかにシワを改善しており、さらに、光老化により悪化する柔軟性や色調までもが改善されたことが分かる。また、本発明のスキンローションによる刺激や痒み等の皮膚の異常は認められなかった。   From this test result, it can be seen that the skin lotion of Example 3 clearly improved the wrinkles as compared with Comparative Example 2, and further improved the flexibility and color tone deteriorated by photoaging. In addition, skin abnormalities such as irritation and itching due to the skin lotion of the present invention were not observed.

実施例4(スキンクリーム)
製造例1のファルネシル酢酸メチルエステルを配合したスキンクリームを下記組成と製法にて調製した。
Example 4 (skin cream)
A skin cream blended with farnesyl acetate methyl ester of Production Example 1 was prepared by the following composition and production method.

(組成)
原 料 成 分 配合量(%)
A成分
(1)密ロウ 2.0
(2)ステアリン酸 5.0
(3)ステアリルアルコール 5.0
(4)還元ラノリン 2.0
(5)スクワレン 20.0
(6)モノステアレートソルビタン 3.0
(7)モノステアレート
ポリオキシエチレン(20)ソルビタン 3.0
(8)プロピレングリコ−ル 5.0
B成分
(9)メチルパラベン 0.2
(10)精製水 残 量
C成分
(11)ファルネシル酢酸メチルエステル 2.0
(composition)
Ingredients Component Amount (%)
A component (1) dense wax 2.0
(2) Stearic acid 5.0
(3) Stearyl alcohol 5.0
(4) Reduced lanolin 2.0
(5) Squalene 20.0
(6) Monostearate sorbitan 3.0
(7) Monostearate Polyoxyethylene (20) Sorbitan 3.0
(8) Propylene glycol 5.0
Component B (9) Methylparaben 0.2
(10) Purified water remaining amount C component (11) farnesyl acetic acid methyl ester 2.0

(製法)
C成分のファルネシル酢酸メチルエステルをB成分に配合した後、A,B成分を各々80℃に加熱溶解し、混合して撹拌しつつ、30℃まで冷却してスキンクリ−ムを調製した。
(Manufacturing method)
After blending C component farnesyl acetic acid methyl ester into component B, each of components A and B was heated and dissolved at 80 ° C., mixed and stirred, and cooled to 30 ° C. to prepare a skin cream.

事前アンケートで目尻のシワを肌悩みとして挙げた20名の健常人(女性,50〜55歳)に、前記スキンクリームを1週間以上使用してもらった。シワの状態に関して下記項目のアンケート調査を行い、各項目ごとに使用前と比較して使用後にそう思うと回答した人の人数を以下に示した。   Twenty healthy persons (women, 50-55 years old) who listed wrinkles in the corners of their eyes as a skin problem in a preliminary questionnaire were asked to use the skin cream for over a week. The following items were surveyed on the wrinkle condition, and the number of people who answered that they thought so after using each item compared to before using was shown below.

−−−−−−−−−−−−−−−−−−−
項目 人数(名)
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった 19
シワの大きさが減少した 17
シワの数が減少した 5
シワが増えた 0
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 19
Wrinkle size decreased 17
Number of wrinkles decreased 5
Increased wrinkles 0
-------------------

本試験結果から実施例4のスキンクリームは、使用前と比較してシワが目立たなくなったと実感しているヒトがほぼ全員で、その要因としてシワの数よりもシワの大きさを軽減することで、光老化によるシワを改善したことが分かる。また、本発明のスキンクリームによる刺激や痒み等の皮膚の異常は認められなかった。   From this test result, the skin cream of Example 4 is almost all humans who feel that wrinkles are less noticeable than before use, and the factor is that the size of wrinkles is reduced rather than the number of wrinkles. It can be seen that wrinkles due to photoaging were improved. In addition, skin abnormalities such as irritation and itching with the skin cream of the present invention were not observed.

皮膚化粧料や外用剤として医薬品や入浴剤等に適用でき、剤型的には例えばロ−ション類、乳液類、クリ−ム類、パック類等とすることができ、皮膚の美容の面から非常に有用である。
It can be applied to skin care cosmetics and external preparations, such as pharmaceuticals and baths, and can be formulated into lotions, milks, creams, packs, etc. Very useful.

Claims (1)

下記一般式(1)
Figure 0003826132
(但し、式中Rは炭素原子数1〜9の直鎖又は分岐鎖状の、飽和又は不飽和炭化水素基を示す)で表されるファルネシル酢酸エステルの少なくとも一種以上を配合することを特徴とするシワ改善剤。
The following general formula (1)
Figure 0003826132
(Wherein R represents a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 9 carbon atoms) and at least one kind of farnesyl acetate represented by: Wrinkle improving agent.
JP2003417604A 2003-12-16 2003-12-16 Wrinkle improving agent Expired - Fee Related JP3826132B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003417604A JP3826132B2 (en) 2003-12-16 2003-12-16 Wrinkle improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003417604A JP3826132B2 (en) 2003-12-16 2003-12-16 Wrinkle improving agent

Publications (2)

Publication Number Publication Date
JP2005179189A JP2005179189A (en) 2005-07-07
JP3826132B2 true JP3826132B2 (en) 2006-09-27

Family

ID=34780055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003417604A Expired - Fee Related JP3826132B2 (en) 2003-12-16 2003-12-16 Wrinkle improving agent

Country Status (1)

Country Link
JP (1) JP3826132B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6668039B2 (en) * 2015-10-22 2020-03-18 ポーラ化成工業株式会社 Melanin production inhibitor

Also Published As

Publication number Publication date
JP2005179189A (en) 2005-07-07

Similar Documents

Publication Publication Date Title
JP4584991B2 (en) Skin cosmetics and wrinkle improvers
US5520918A (en) Low irritant skin-cosmetic composition for daily topical use, its application and manufacture
EP1216696B1 (en) Method for reducing the appearance of dark circles under the eyes
JP4567732B2 (en) Skin cosmetics and wrinkle improvers
JP2007532521A (en) Use of sphingoid bases associated with nicotinic acid or nicotinamide in the form of depigmenting agents
JP2004091376A (en) Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
CN1357321A (en) Inflammation and red spot reducing method
JP4579564B2 (en) Wrinkle improving agent
JP4934280B2 (en) Wrinkle improving agent
JP3826132B2 (en) Wrinkle improving agent
JP4488933B2 (en) Wrinkle improving agent and external composition for skin
JP4456918B2 (en) Wrinkle improving agent
JP2006248953A (en) Wrinkle ameliorating agent and external composition for skin
JP4359197B2 (en) Wrinkle improving agent and skin cosmetic
JPH11228438A (en) Preparation for external use for skin
JPH06271446A (en) Wrinkle improver
JP3382146B2 (en) External preparation for skin
JP5244284B2 (en) Wrinkle improving agent
RU2119790C1 (en) Agent for biological skin rejuvenation
JPH0761919A (en) Bautifying agent
JP4359235B2 (en) Wrinkle improving agent and skin cosmetic
JP5768114B2 (en) Method for producing an external preparation for aging
JP2022037267A (en) Topical preparation for preventing and/or improving xanthoderma
JP2002514203A (en) Composition for promoting skin or hair

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050615

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060703

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100707

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110707

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110707

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120707

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120707

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130707

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees